Enbiosis, a leading company in the field of personalized nutrition, has conducted a groundbreaking study comparing a microbiome-based personalized diet with a commonly administered diet for patients with irritable bowel syndrome (IBS). This study aims to address the limitations of the low FODMAP diet, which provides symptom relief but fails to consider the patient’s microbiome.
The investigation involved 41 IBS patients who followed either a personalized diet (PD) or a low FODMAP diet (LFD) for six weeks. The objective measure of gut microbiome composition, determined through fecal analysis, showed that the personalized diet outperformed the low FODMAP diet in 7 out of 11 indices. Although the difference was not statistically significant, the consistent superiority of the personalized diet indicates its potential effectiveness.
One significant finding was that the personalized diet improved the quality of life for all subgroups of IBS, while the low FODMAP diet only demonstrated such improvements for IBS-Constipation. This emphasizes the crucial role of personalization in addressing diverse needs within the same syndrome.
Enbiosis’s research on AI-assisted personalized microbiome modulation builds on previous studies published in reputable journals. This innovative approach combines artificial intelligence and microbiome science to provide personalized diet and supplement recommendations.
Enbiosis has developed a proprietary genetic algorithm that determines gut composition and relationships among bacteria from mail-in fecal samples. This information informs individualized microbiome analysis reports, enabling Enbiosis to offer personalized diet plans. Additionally, Enbiosis has integrated technology that mines restaurant menus online, facilitating microbiome-aligned orders.
Enbiosis is also in negotiations with a prominent supplement supplier in the USA for a potential partnership in the North American market. This partnership will enable Enbiosis to offer personalized diet and prebiotic/probiotic suggestion products, aligning with the company’s mission to provide targeted nutrition solutions.
As Enbiosis continues to expand its offerings, forthcoming studies evaluating the prebiotic and probiotic suggestion engine, as well as clinical trials for the new blood glucose regulatory algorithm, are expected to provide valuable insights and contribute to the advancement of personalized nutrition.
In conclusion, Enbiosis’s research demonstrates the potential of microbiome-based personalized diets in improving the well-being of IBS patients. By considering individual microbiome composition and leveraging AI technology, Enbiosis offers customized nutrition plans and aims to enhance the quality of life for individuals with diverse needs.
